Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Favorable five-year outcomes for heart failure diagnosed in younger patients without severe comorbidity

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Prevalence and incidence of various Cancer subtypes in patients with heart failure vs matched controls

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Infarct size following loading with Ticagrelor/Prasugrel versus Clopidogrel in ST-segment elevation myocardial infarction

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. The cardiac isovolumetric contraction time is an independent predictor of incident heart failure in the general population

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Carotid atherosclerosis markers and adverse cardiovascular events

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  5. Cardiovascular complications in patients with total cavopulmonary connection: A nationwide cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Switching from Vitamin K Antagonist to Dabigatran in Atrial Fibrillation: Differences According to Dose

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Vitamin K antagonists vs. direct oral anticoagulants after transcatheter aortic valve implantation in atrial fibrillation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Pulmonary Arterial Enlargement in Well-Treated Persons With Human Immunodeficiency Virus

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Left ventricular myocardial crypts: morphological patterns and prognostic implications

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Left ventricular trabeculation and major adverse cardiovascular events: the Copenhagen General Population Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Christian Madelaire
  • Finn Gustafsson
  • Lynne Warner Stevenson
  • Søren Lund Kristensen
  • Lars Køber
  • Julie Andersen
  • Maria D'Souza
  • Christian Torp-Pedersen
  • Gunnar Gislason
  • Morten Schou
Vis graf over relationer

Background: Heart failure (HF) is widely associated with a median survival of 5 years. However, population level data on survival and HF progression has been limited for key subgroups. We assessed survival and HF progression, defined as hospitalization or outpatient diuretic intensification in patients ≤70 years without severe comorbidity, who received relevant medical therapy. Methods: From administrative registers, we identified all Danish patients ≤70 years diagnosed with HF 2000–2012 without severe comorbidity, survived for 120 days to receive angiotensin converting enzyme inhibitors (ACE-I)/angiotensin receptor blocker (ARB) and beta blocker. Risk of death or progression of HF was assessed with Kaplan-Meier and Aalen Johansen estimators, respectively. Cox regression models were used to identify factors associated with risk of death. Results: We included 19,985 patients, median age 61, 25% women - 1/3 of all HF patients ≤70 years. We excluded 237 patients who died within 120 days and 21,065 due to severe comorbidity. Five-year cumulative incidence of all-cause death was 14% (95%-confidence interval [CI]:13–14). Risk of death was increased for patients first diagnosed in hospital compared to outpatient clinics (hazard ratio: 1.51, 95%-CI:1.38–1.65, p < 0.001). Five-year cumulative incidence of HF hospitalization: 18% (95%-CI, 18–19) and intensification of diuretic therapy: 14% (95%-CI, 14–15). Conclusions: In patients ≤70 years without severe comorbidity, five-year mortality was only 14% and almost 2/3 were alive after 5 years without evident HF progression. Discussion of prognosis should be tailored to age and health status to provide realistic expectations for patients newly diagnosed and treated with recommended therapies for HF.

OriginalsprogEngelsk
TidsskriftInternational Journal of Cardiology
Vol/bind305
Sider (fra-til)106-112
Antal sider7
ISSN0167-5273
DOI
StatusUdgivet - 15 apr. 2020

Bibliografisk note

Copyright © 2020 Elsevier B.V. All rights reserved.

ID: 59211142